Market News

Bnp Paribas Arbitrage Sa Has Decreased Agios Pharmaceuticals (AGIO) Holding by $122.23 Million; As Pacira Pharmaceuticals (PCRX) Shares Declined, Holder Aristeia Capital Has Decreased Its Stake by $1.35 Million

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Logo

Bnp Paribas Arbitrage Sa decreased its stake in Agios Pharmaceuticals Inc (AGIO) by 17.5% based on its latest 2017Q4 regulatory filing with the SEC. Bnp Paribas Arbitrage Sa sold 2,138 shares as the company’s stock rose 38.11% while stock markets declined. The institutional investor held 10,078 shares of the health care company at the end of 2017Q4, valued at $576.16M, down from 12,216 at the end of the previous reported quarter. Bnp Paribas Arbitrage Sa who had been investing in Agios Pharmaceuticals Inc for a number of months, seems to be less bullish one the $5.00 billion market cap company. The stock decreased 0.14% or $0.12 during the last trading session, reaching $87.21. About 153,185 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 41.40% since April 16, 2017 and is uptrending. It has outperformed by 29.85% the S&P500.

Robert Henry Lynch decreased its stake in Pacira Pharmaceuticals Inc (PCRX) by 31.65% based on its latest 2017Q4 regulatory filing with the SEC. Aristeia Capital Llc sold 30,000 shares as the company’s stock declined 27.90% with the market. The hedge fund run by Robert Henry Lynch held 64,800 shares of the health care company at the end of 2017Q4, valued at $2.96 million, down from 94,800 at the end of the previous reported quarter. Aristeia Capital Llc who had been investing in Pacira Pharmaceuticals Inc for a number of months, seems to be less bullish one the $1.41 billion market cap company. The stock increased 3.59% or $1.2 during the last trading session, reaching $34.65. About 228,683 shares traded. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has declined 33.05% since April 16, 2017 and is downtrending. It has underperformed by 44.60% the S&P500.

Among 22 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 10 have Buy rating, 1 Sell and 11 Hold. Therefore 45% are positive. Pacira Pharmaceuticals had 103 analyst reports since July 28, 2015 according to SRatingsIntel. BMO Capital Markets maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Wednesday, November 8 with “Hold” rating. Wedbush maintained the stock with “Buy” rating in Thursday, April 5 report. The company was maintained on Monday, August 7 by Wedbush. The firm has “Buy” rating given on Wednesday, February 22 by Canaccord Genuity. Wedbush maintained the shares of PCRX in report on Wednesday, December 20 with “Buy” rating. The rating was maintained by Jefferies with “Buy” on Monday, September 26. Cowen & Co maintained the stock with “Hold” rating in Wednesday, August 2 report. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, January 4. The firm has “Buy” rating by Seaport Global given on Tuesday, March 20. Mizuho maintained the stock with “Buy” rating in Wednesday, October 18 report.

Since December 15, 2017, it had 0 buys, and 2 sales for $1.18 million activity. On Friday, December 15 the insider Riker Lauren Bullaro sold $14,858.

Aristeia Capital Llc, which manages about $6.79B and $2.35B US Long portfolio, upped its stake in Hostess Brands Inc by 682,445 shares to 6.98M shares, valued at $16.28 million in 2017Q4, according to the filing. It also increased its holding in Entercom Communications Corp (NYSE:ETM) by 3.66 million shares in the quarter, for a total of 3.91M shares, and has risen its stake in Herbalife Ltd (Prn).

Analysts await Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to report earnings on May, 3. They expect $-0.33 EPS, up 13.16% or $0.05 from last year’s $-0.38 per share. After $0.18 actual EPS reported by Pacira Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -283.33% negative EPS growth.

Investors sentiment increased to 1.4 in Q4 2017. Its up 0.01, from 1.39 in 2017Q3. It is positive, as 29 investors sold PCRX shares while 41 reduced holdings. 31 funds opened positions while 67 raised stakes. 40.06 million shares or 3.76% less from 41.63 million shares in 2017Q3 were reported. 288,887 are held by Oak Ridge Investments Lc. Ontario – Canada-based Manufacturers Life Insurance The has invested 0% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Financial Bank Of New York Mellon accumulated 0% or 223,157 shares. Deutsche Bancshares Ag holds 0.01% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) or 339,933 shares. Baillie Gifford Com invested 0.02% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Moreover, New York State Common Retirement Fund has 0.01% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 183,130 shares. Malaga Cove Ltd holds 20,687 shares or 0.53% of its portfolio. Rhumbline Advisers invested in 0% or 39,592 shares. Denver Inv Advsr Lc, Colorado-based fund reported 12,552 shares. Renaissance Technology Limited Liability owns 509,900 shares or 0.03% of their US portfolio. Stephens Inv Management Ltd Liability Corporation stated it has 1.06% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Westfield Capital Mgmt Limited Partnership has invested 0.43% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Citadel Advsr Ltd invested 0.01% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Aristeia Capital Ltd Llc holds 64,800 shares or 0.13% of its portfolio. Bouchey Gru invested in 0.06% or 4,500 shares.

Since January 10, 2018, it had 1 buy, and 19 insider sales for $16.87 million activity. The insider Schenkein David P sold $1,600. Another trade for 3,000 shares valued at $249,229 was made by Biller Scott on Monday, March 5. On Thursday, February 22 the insider Hoerter Steven L. sold $161,192. 6,800 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares with value of $557,396 were sold by Foster-Cheek Kaye I. Another trade for 2,150 shares valued at $161,250 was sold by Alenson Carman. Another trade for 200 shares valued at $16,688 was made by Scadden David on Friday, March 16.

Bnp Paribas Arbitrage Sa, which manages about $56400.55 billion US Long portfolio, upped its stake in Home Depot Inc/The (Put) (NYSE:HD) by 1.03M shares to 1.03 million shares, valued at $194.89 billion in 2017Q4, according to the filing. It also increased its holding in Procter And Gamble Co/The (Put) (NYSE:PG) by 643,983 shares in the quarter, for a total of 646,600 shares, and has risen its stake in Pricesmart Inc (NASDAQ:PSMT).

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 45 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Buy” rating by Cowen & Co on Tuesday, June 6. SunTrust maintained it with “Buy” rating and $80.0 target in Tuesday, October 3 report. Credit Suisse maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Wednesday, April 11 with “Outperform” rating. The firm has “Outperform” rating by Leerink Swann given on Wednesday, August 2. Canaccord Genuity maintained the stock with “Buy” rating in Monday, June 5 report. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Outperform” rating by Oppenheimer on Tuesday, January 17. The rating was maintained by Roth Capital on Wednesday, August 5 with “Hold”. On Monday, June 13 the stock rating was upgraded by Canaccord Genuity to “Buy”. As per Thursday, January 21, the company rating was initiated by Credit Suisse. The rating was maintained by Roth Capital on Monday, November 9 with “Neutral”.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *